13 results about "Inhibitory molecules" patented technology

A combination therapy comprising a semaphorin-4D inhibitory molecule and Flt3 ligand or a FLT3 agonist with or without a checkpoint inhibitor for treating cancer is disclosed.

The present disclosure relates to a cell-based assay for determining in vitro tumor killing activity of immune cells expressing a chimeric antigen. The present disclosure provides an in vitro method for determining the potency (e.g., cytotoxicity) of immune cells expressing a chimeric antigen receptor (CAR) molecule. In a test sample, the CAR-expressing immune cells are incubated with target cells that express an antigen that interacts with the CAR. In a control sample, the CAR-expressing immune cells are incubated with the target cells and an inhibitory molecule that prevents the interaction between the CAR and the target cells. The amount of target cell death is determined in both the test sample and the control sample and compared.

The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).

The present invention relates to lipid-based nanoparticles comprising an antigen-binding domain capable of specifically binding to a target expressed on the surface of activated immune cells, and one or more mRNA molecules encoding an inhibitory protein of the activated immune cells, and to the use thereof.

This invention belongs to the field of biomedicine and discloses the application of palmitoyltransferase ZDHHC21 in the preparation of drugs for treating breast cancer. This invention demonstrates that ZDHHC21 knockdown upregulates RIPK1 expression, which is related to signal feedback induced by CD82 palmitoylation deficiency. Depalmitoylated CD82 competitively binds to RIPK1 inhibitory molecules, thereby releasing the regulation of RIPK1, promoting the interaction and phosphorylation activation of RIPK1 and RIPK3, and subsequently upregulating MLKL expression and inducing its activation. Downstream activation of Caspase-3 ultimately initiates necroptosis. A specific regulatory axis of "ZDHHC21–CD82–pan-apoptosis" is established. This provides a potential novel therapeutic target for triple-negative breast cancer and offers a theoretical and experimental basis for therapeutic strategies targeting tumor cell death. Further research can explore the role of this regulatory axis in vivo, providing support for clinical translation.

This invention discloses a near-infrared II photothermal therapeutic agent, its preparation method, and its application, belonging to the field of optical diagnostics and treatment technology. To address the problems of insufficient light absorption, fluorescence quenching, and inadequate molecular structure optimization in existing photothermal therapeutic agents, this invention proposes a molecular design strategy of "central plane + peripheral twisting," developing a novel NIR-II photothermal therapeutic agent, 4TPE-TB, which is a near-infrared II photothermal therapeutic agent. This invention enhances the light absorption capacity of the near-infrared II photothermal therapeutic agent by strengthening the conjugation of the molecular core, and utilizes the peripheral twisted structure to suppress intermolecular stacking, significantly improving photothermal conversion efficiency and fluorescence performance, thereby achieving a comprehensive improvement in the therapeutic agent's performance.

The application discloses a kind of drug composition containing antibody drug conjugate and application thereof.The application provides a kind of drug composition 1, it includes compound C, histidine buffer, saccharide stabilizer, surfactant and water, the pH of the described drug composition 1 is 6.0-6.5;Wherein, the compound C is A-(B) n The drug composition of the application can be long-term stably stored in liquid form without freeze-drying, can effectively inhibit the aggregation and degradation of ADC molecules, has excellent biological activity and safety, greatly improves the convenience of clinical application while reducing the production cost.Meanwhile, the drug composition of the application can also maintain good stability after freeze-drying treatment and reconstitution, providing more options for clinical application.

This invention provides an antibody or antigen fragment thereof that targets human-derived CD7 and its use. CD7-CARs based on this antibody and antibody fragment have very high affinity for the CD7 antigen molecule, and inhibitory molecules containing this antibody can almost completely inhibit the expression of the CD7 molecule on the cell surface without affecting the normal amplification of T cells, thus effectively avoiding sibling killing of CD7-CAR-T cells. CD7-CAR-T cells constructed using a single-domain antibody that targets human-derived CD7 have a high killing effect on target cells.

The application discloses an assembly synergistic near-infrared two-region nanoparticle based on an electron-rich polymer and a preparation method and application thereof, and belongs to the technical field of precise optical diagnosis and treatment of major diseases such as tumors, and proposes an assembly synergistic strategy, takes an electron-rich block polymer as a carrier, forms an intermolecular electron donor-electron acceptor unit between the carrier and a near-infrared two-region molecule, reduces the singlet and triplet energy level difference of the molecule, promotes inter-gap crossing, effectively inhibits molecular vibration, and thus improves the diagnosis and treatment performance. Compared with a traditional performance optimization method at the molecular level, the application adopts a simple and easy self-assembly strategy, successfully overcomes the problems of low active oxygen yield and low fluorescence quantum yield of the near-infrared two-region optical diagnosis and treatment material, can provide a new and effective means for the precise diagnosis and treatment of major diseases such as tumors, and has a wide application prospect.

The present invention relates to an inhibitor of heat shock protein 90. Disclosed are a heat shock protein 90-based bivalent inhibitor, and a preparation method therefor and the use thereof. The bivalent inhibitor is a compound having a structural formula as shown in formula I: A-L-B Formula I, or a pharmaceutically acceptable salt, solvate, or optical isomer thereof, wherein A and B are ATP inhibitors of heat shock protein 90, and the motif structure of L is a flexible linker group of PEG or alkanes, or a rigid linker group comprising aryl, heteroalkyl, or heteroaryl. The bivalent inhibitor can effectively inhibit the activity of molecular chaperone HSP90, hinder the folding and modification of a substrate protein, degrade the substrate protein via a ubiquitin-proteasome degradation pathway, induce non-native dimerization of HSP90, and interfere with protein-protein interactions associated with HSP90. In addition, the bivalent inhibitor reduces the heat shock response induced by HSP90 inhibition, and exhibits potent activity in degrading the substrate protein.

The present disclosure relates to cell-based assays for determining in vitro tumor killing activity of immune cells expressing chimeric antigens. The present disclosure provides an in vitro method for determining the potency (e.g., cytotoxicity) of an immune cell expressing a chimeric antigen receptor (CAR) molecule. In a test sample, immune cells that express the CAR are incubated with target cells that express antigens that interact with the CAR. In a control sample, an immune cell expressing the CAR is incubated with a target cell and an inhibitory molecule that prevents interaction between the CAR and the target cell. The amount of target cell death in both the test sample and the control sample is determined and compared.